Published Date: 04 Mar 2023
A new study by Robin von Rotz and his team found that moderate doses of psilocybin for at least two weeks reduced symptoms of depression...
Read Full NewsRoshen Mathew, MD, DAABIP, discusses STABLE, in which diagnostic yield was 86.8% with breath-hold vs 92.2% with conventional ventilation.
Sara Cuccurullo, MD, FAAPMR, and Talya Fleming, MD, FAAPMR, of Hackensack Meridian JFK Johnson Rehabilitation Institute, discuss the updated adult stroke rehabilitation and recovery guidelines and their implications for clinical practice.
1.
Laser Therapy Shows Promise for Brain Tumors
2.
NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.
3.
Renewing the call for a national Cancer Patient's Bill of Rights
4.
Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.
5.
Cancer cells with thick glycocalyx barrier evade immune system better: study
1.
Comprehensive Applications in Oncology and Quality Improvement
2.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer
5.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
2.
From Guidelines to Practice: Hematology
3.
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation